Technical Analysis for ESLA - Estrella Immunopharma, Inc.

Grade Last Price % Change Price Change
D 0.92 8.17% 0.07
ESLA closed up 8.17 percent on Wednesday, November 20, 2024, on 20 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Flat Up

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Upper Bollinger Band Touch Strength 0.00%
NR7 Range Contraction 8.17%
Narrow Range Bar Range Contraction 8.17%
Inside Day Range Contraction 8.17%
Gapped Down Weakness 8.17%
20 DMA Support Bullish 3.44%
Inside Day Range Contraction 3.44%
20 DMA Support Bullish 3.43%

   Recent Intraday Alerts

Alert Time
Up 1% about 22 hours ago
Possible NR7 1 day ago
Possible Inside Day 1 day ago
Down 3% 2 days ago
Down 2 % 2 days ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Estrella Immunopharma, Inc. Description

Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMISĀ® T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer. To accomplish this mission, Estrella's lead product candidate, EB103, utilizes Eureka's ARTEMISĀ® technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. Estrella is also developing EB104, which also utilizes Eureka's ARTEMISĀ® technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. Estrella is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus ("CF33-CD19t"), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors using a "mark and kill" strategy.


Classification

Sector: Financial Services
Industry: Shell Companies
Keywords: Cancer Solid Tumors Immune System Blood Cancers CD19 Oncolytic Virus Preclinical Stage Biopharmaceutical Cd22

Is ESLA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.23
52 Week Low 0.63
Average Volume 160,361
200-Day Moving Average 1.10
50-Day Moving Average 0.92
20-Day Moving Average 0.83
10-Day Moving Average 0.83
Average True Range 0.11
RSI (14) 55.16
ADX 18.14
+DI 20.36
-DI 17.20
Chandelier Exit (Long, 3 ATRs) 0.66
Chandelier Exit (Short, 3 ATRs) 0.96
Upper Bollinger Bands 0.94
Lower Bollinger Band 0.72
Percent B (%b) 0.91
BandWidth 26.14
MACD Line -0.01
MACD Signal Line -0.03
MACD Histogram 0.021
Fundamentals Value
Market Cap 32.4 Million
Num Shares 35.2 Million
EPS -0.20
Price-to-Earnings (P/E) Ratio -4.60
Price-to-Sales 0.00
Price-to-Book 4.27
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.12
Resistance 3 (R3) 1.12 1.06 1.09
Resistance 2 (R2) 1.06 1.01 1.06 1.08
Resistance 1 (R1) 0.99 0.97 1.02 0.99 1.07
Pivot Point 0.92 0.92 0.94 0.92 0.92
Support 1 (S1) 0.85 0.87 0.89 0.85 0.77
Support 2 (S2) 0.79 0.84 0.79 0.76
Support 3 (S3) 0.72 0.79 0.75
Support 4 (S4) 0.72